Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

LL-37vsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BPhase 2HUMAN-REVIEWED8/46 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Membrane disruptionPrimary mechanismLu 2026He 2026
Innate immunityHost defense rolePinheiro 2026Zhang 2026
Endogenous · Secreted at inflammation sites
TB-500
Thymosin β4 fragment · Healing
2 mgPer doseGoldstein 2012
Phase 2Evidence levelGoldstein 2012
~2 hrHalf-life
SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter
LL-37
TB-500
Primary target
Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026Lu 2026
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
Endogenous protein at baseline; supplementation amplifies
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development

02Dosage Protocols

Parameter
LL-37
TB-500
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
Evidence basis
In vitro, animal models, human observational
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Standard dose
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
2× per week (loading); then 1× per week (maintenance)
Lower / starter dose
1 mg per injection
Duration
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
Evening or pre-rest preferred (anecdotal)
Half-life
~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter
LL-37
TB-500
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Biofilm formation risk
LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
Injection site reaction
Mild erythema, transient pain
GI symptoms
Rare nausea (anecdotal)
Cancer risk
Theoretical via angiogenesis pathway
Lethargy / fatigue
Reported anecdotally during loading phase
Antibody formation
No data (no long-term human trials)
Pregnancy / OB
Avoid
Long-term safety
Unknown beyond Phase 2
Absolute Contraindications
LL-37
TB-500
  • ·Active malignancy (theoretical angiogenesis concern)
  • ·Pregnancy / breastfeeding
Relative Contraindications
LL-37
  • ·Active autoimmune disease (theoretical immune dysregulation)
TB-500
  • ·Cancer history
  • ·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter
LL-37
TB-500
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
27–31G, 4–8 mm insulin syringe.

06Stack Synergy

LL-37
— no documented stacks
TB-500
+ BPC-157
Strong
View BPC-157

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500
2 mg SQ · 2× per week
BPC-157
250–500 mcg SQ · daily
Primary benefit
Combined angiogenesis + cell migration for tendon/ligament/muscle repair